SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (39422)11/29/2012 8:27:37 AM
From: Biotech Jim  Respond to of 52153
 
Peter- I had not seen the abstract that you posted, but will dig into it. Here is another paper that is of interest along the same lines, published in Neuron:

JNK3 perpetuates metabolic stress induced by Aß peptides.
Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, Lim TH, Pastorino L, Kunwar AJ, Walton JC, Nagahara AH, Lu KP, Nelson RJ, Tuszynski MH, Huang K.
Source Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH 43210, USA. sung.yoon@osumc.edu

Abstract Although Aß peptides are causative agents in Alzheimer's disease (AD), the underlying mechanisms are still elusive. We report that Aß42 induces a translational block by activating AMPK, thereby inhibiting the mTOR pathway. This translational block leads to widespread ER stress, which activates JNK3. JNK3 in turn phosphorylates APP at T668, thereby facilitating its endocytosis and subsequent processing. In support, pharmacologically blocking translation results in a significant increase in Aß42 in a JNK3-dependent manner. Thus, JNK3 activation, which is increased in human AD cases and a familial AD (FAD) mouse model, is integral to perpetuating Aß42 production. Concomitantly, deletion of JNK3 from FAD mice results in a dramatic reduction in Aß42 levels and overall plaque loads and increased neuronal number and improved cognition. This reveals AD as a metabolic disease that is under tight control by JNK3.

Copyright © 2012 Elsevier Inc. All rights reserved.

I have the pdf if anyone wants a copy - send me a PM.

Jim



To: Biomaven who wrote (39422)11/30/2012 7:40:32 AM
From: idos  Respond to of 52153
 
This is the 2nd recent big push for the neuroinflammation hypothesis of AD, the TREM2 mutations being the other:

nejm.org